M42 Group’s Cleveland Clinic Abu Dhabi and Canadian digital health startup BioTwin, part of Abu Dhabi’s global tech ecosystem Hub71, have established a partnership at Arab Health 2025 to validate BioTwin’s virtual human twin technology by creating unique patient profiles for breast cancer screening.
BioTwin’s virtual twin technology, currently in its trial phase, uses advanced data analytics, machine learning, and biological biomarkers to create detailed digital replicas of individual patients. These dynamic and personalised virtual twins enable continuous monitoring and early disease detection, such as breast cancer, by identifying subtle changes that correlate with the disease’s profile potentially signaling its onset.
The pilot project will run on Microsoft Azure. BioTwin is part of the Microsoft Entrepreneurship for Positive Impact initiative, which supports entrepreneurs committed to solving the world’s most pressing challenges through access to training, mentorship, Azure credits, and partnership opportunities.
According to Dr. Rafal Iskanderian, Staff Physician, General Surgery, Oncology Institute at Cleveland Clinic Abu Dhabi, by leveraging virtual twin technology, the partnership aims to enhance early detection capabilities, potentially saving lives and improving patient outcomes.